Regulation of Glioblastoma Stem-Like Cells by CDC20-Anaphase-Promoting Complex
CDC20-后期促进复合物对胶质母细胞瘤干细胞样细胞的调节
基本信息
- 批准号:9176497
- 负责人:
- 金额:$ 33.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAlkylating AgentsBindingCell LineCell physiologyCellsCellular biologyChIP-seqCollaborationsDNADataData SetDevelopmentDiagnosisDiseaseEffectivenessExhibitsGenomicsGlioblastomaGoalsHumanHuman CharacteristicsIn VitroIonizing radiationKnowledgeLaboratoriesLifeMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMapsMediatingMitoticMolecularPathway interactionsPatientsPlayPrimary Brain NeoplasmsPropertyProteinsRNA InterferenceRadiation therapyRadiobiologyRecurrenceRegulationReportingResistanceRoleSignal PathwaySignal TransductionStem cellsStructureTestingTherapeuticTumor-DerivedUniversitiesWashingtonXenograft Modelanaphase-promoting complexanimal imagingbasebody systemcancer cellcancer recurrencecancer stem cellchemotherapeutic agentchemotherapyclinically relevantcombatconventional therapyeffective therapygenome-wideimprovedin vivomultidisciplinarynovelnovel strategiesnovel therapeuticsoutcome forecastoverexpressionpluripotencypreventprogramsprotein complexresearch studyresponseself-renewalstandard of carestemtemozolomidetherapy resistanttranscription factortranscriptome sequencingtreatment responsetumortumor growthtumor initiationubiquitin-protein ligase
项目摘要
ABSTRACT
Glioblastoma is the most common malignant primary brain tumor in adults and is invariably fatal. Glioblastoma
stem-like cells (GSCs) represent a dynamic subpopulation of glioblastoma cells, which are now known to
exhibit treatment resistance and cause tumor recurrence. Therefore, knowledge of the mechanisms governing
the GSC state is essential to develop effective therapies against glioblastoma. Using patient-derived
glioblastoma cell lines, we have recently uncovered a requirement for the E3 ligase CDC20-Anaphase-
Promoting Complex (CDC20-APC) in key GSC functions of invasion, self-renewal, and tumor initiation.
Furthermore, we have identified the pluripotency regulatory transcription factor SOX2 as a novel CDC20-
interacting protein, which mediates the downstream effects of CDC20-APC in GSCs in vitro. How exactly the
CDC20-APC/SOX2 signaling pathway is regulated in GSCs and what role the CDC20-APC/SOX2 pathway
plays in glioblastoma in vivo remain to be defined. The goals of our proposal are: 1) to identify the molecular
mechanisms underlying the CDC20-APC/SOX2 pathway in GSC invasiveness, 2) to determine the impact of
the CDC20-APC/SOX2 pathway on tumor initiation and maintenance in glioblastoma in vivo, and 3) to
determine the effect of the CDC20-APC/SOX2 pathway on GSC responsiveness to standard-of-care
chemotherapy temozolomide and radiation therapy. The long-term goal of this project is to develop novel
CDC20-APC-directed therapeutic strategies to disrupt the GSC state and enhance the effectiveness of current
treatments.
摘要
胶质母细胞瘤是成人中最常见的恶性原发性脑肿瘤,并且总是致命的。胶质瘤
干细胞样细胞(GSC)代表胶质母细胞瘤细胞的动态亚群,现在已知其
表现出治疗抗性并导致肿瘤复发。因此,了解管理机制
GSC状态对于开发针对胶质母细胞瘤的有效疗法至关重要。使用患者来源的
在胶质母细胞瘤细胞系中,我们最近发现了E3连接酶CDC 20-后期-
促进复合物(CDC 20-APC)在GSC的侵袭、自我更新和肿瘤起始的关键功能中的作用。
此外,我们已经确定了多能性调节转录因子SOX 2作为一种新的CDC 20 - 21。
相互作用蛋白,其在体外介导⑶ C20-APC在GSC中的下游作用。到底是怎么回事
CDC 20-APC/SOX 2信号通路在GSC中受到调节,以及CDC 20-APC/SOX 2通路在GSC中的作用
在体内胶质母细胞瘤中的作用仍有待确定。我们的目标是:1)确定分子
CDC 20-APC/SOX 2通路在GSC侵袭中的潜在机制,2)确定
CDC 20-APC/S 0X 2通路在体内胶质母细胞瘤中对肿瘤起始和维持的作用,和3)
确定CDC 20-APC/SOX 2通路对GSC对标准治疗反应性的影响
化疗替莫唑胺和放疗。该项目的长期目标是开发新的
CDC 20-APC-导向的治疗策略,以破坏GSC状态并增强目前的治疗效果。
治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Albert Hong-Jae Kim其他文献
Albert Hong-Jae Kim的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Albert Hong-Jae Kim', 18)}}的其他基金
Mechanisms of SOX2 Regulation in Glioblastoma
SOX2 在胶质母细胞瘤中的调控机制
- 批准号:
10504032 - 财政年份:2022
- 资助金额:
$ 33.36万 - 项目类别:
Mechanisms of SOX2 Regulation in Glioblastoma
SOX2 在胶质母细胞瘤中的调控机制
- 批准号:
10676179 - 财政年份:2022
- 资助金额:
$ 33.36万 - 项目类别:
NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
胶质母细胞瘤肿瘤生长和治疗耐药性中的 NAD 通路信号传导
- 批准号:
10654813 - 财政年份:2019
- 资助金额:
$ 33.36万 - 项目类别:
NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
胶质母细胞瘤肿瘤生长和治疗耐药性中的 NAD 通路信号传导
- 批准号:
10448244 - 财政年份:2019
- 资助金额:
$ 33.36万 - 项目类别:
NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
胶质母细胞瘤肿瘤生长和治疗耐药性中的 NAD 通路信号传导
- 批准号:
10194624 - 财政年份:2019
- 资助金额:
$ 33.36万 - 项目类别:
MECHANISMS OF DENDRITE MORPHOGENESIS BY THE ANAPHASE-PROMOTING COMPLEX
后期促进复合体的枝晶形态发生机制
- 批准号:
8424656 - 财政年份:2012
- 资助金额:
$ 33.36万 - 项目类别:
MECHANISMS OF DENDRITE MORPHOGENESIS BY THE ANAPHASE-PROMOTING COMPLEX
后期促进复合体的枝晶形态发生机制
- 批准号:
8534312 - 财政年份:2012
- 资助金额:
$ 33.36万 - 项目类别:
MECHANISMS OF DENDRITE MORPHOGENESIS BY THE ANAPHASE-PROMOTING COMPLEX
后期促进复合体的枝晶形态发生机制
- 批准号:
8722051 - 财政年份:2012
- 资助金额:
$ 33.36万 - 项目类别:
Mechanisms of glioblastoma multiforme invasion: the role of STAT3
多形性胶质母细胞瘤侵袭机制:STAT3的作用
- 批准号:
7367028 - 财政年份:2006
- 资助金额:
$ 33.36万 - 项目类别:
Mechanisms of glioblastoma multiforme invasion: the role of STAT3
多形性胶质母细胞瘤侵袭机制:STAT3的作用
- 批准号:
7158293 - 财政年份:2006
- 资助金额:
$ 33.36万 - 项目类别:
相似海外基金
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
- 批准号:
10374792 - 财政年份:2021
- 资助金额:
$ 33.36万 - 项目类别:
Elucidation and prevention of the mechanism of hepatic sinusoidal obstruction syndrome (SOS) induced by DNA alkylating agents
DNA烷化剂诱发肝窦阻塞综合征(SOS)机制的阐明和预防
- 批准号:
21K15255 - 财政年份:2021
- 资助金额:
$ 33.36万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
- 批准号:
10570900 - 财政年份:2021
- 资助金额:
$ 33.36万 - 项目类别:
Development of individualized therapy by elucidation of molecular mechanisms for hypermutation phenotype induced by treatment with alkylating agents in glioma
通过阐明神经胶质瘤中烷化剂治疗诱导的超突变表型的分子机制来开发个体化治疗
- 批准号:
18K09004 - 财政年份:2018
- 资助金额:
$ 33.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Reversing intrinsic cancer cell resistance to alkylating agents by histone deacetylase inhibition
通过组蛋白脱乙酰酶抑制逆转癌细胞对烷化剂的内在耐药性
- 批准号:
214657440 - 财政年份:2012
- 资助金额:
$ 33.36万 - 项目类别:
Research Grants
Rerouting alkylating agents to the mitochondria for cancer therapy
将烷化剂重新路由至线粒体用于癌症治疗
- 批准号:
247842 - 财政年份:2011
- 资助金额:
$ 33.36万 - 项目类别:
Studentship Programs
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8105413 - 财政年份:2010
- 资助金额:
$ 33.36万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8271313 - 财政年份:2010
- 资助金额:
$ 33.36万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8730259 - 财政年份:2010
- 资助金额:
$ 33.36万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8676463 - 财政年份:2010
- 资助金额:
$ 33.36万 - 项目类别: